Oct 30, 2017 New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation Learn More
Oct 24, 2017 Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma Learn More
Oct 17, 2017 Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors Learn More
Oct 12, 2017 Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering Learn More